Clinical trial design is a critical factor that can make or break success. Careful foresight in initial stages can impact data quality and trial duration.
TORONTO (PRWEB) April 08, 2020
Targeted therapies are currently the focus of much anti-cancer drug development. They are a cornerstone of precision medicine, using information about a person’s genes and proteins to prevent, diagnose and treat disease. While these therapies show great promise, they are also very complex. These immuno-oncology and cytostatic treatments often require different assumptions and factors to be tested compared to traditional, early safety-based trials for cytotoxic agents. Clinical trial design is a critical factor that can make or break success. Careful foresight in initial stages can impact data quality and trial duration.
This webinar will address leading therapies in novel oncology trials. It will provide an in-depth perspective on what drug developers can do to find the right patients. It will offer insights into just how important biomarkers and companion diagnostics may be in targeted therapy clinical trials.
Attendees will gain important insights from experts developing some of the most innovative oncology clinical trials today.
For more information or to register for this event, visit The Progression of Targeted Therapies: Addressing & Surmounting Complexities in Clinical Development.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.